Eric Patzer

Dr. Patzer is co-founder, former President and current Chairman of the Board of Directors of Aridis Pharmaceuticals, Inc., a company focused on innovative therapies for infectious disease particularly involving antibiotic resistance. Aridis recently completed an initial public offering (IPO) in 2018 and is publicly traded on NASDAQ. He has more than 35 years of experience in biotechnology and since 1981 has been involved in developing many pioneering biotechnology products beginning at Genentech (Activase®, Protropin®, Herceptin® and Xolair®). Then in 1996, he joined Aviron (acquired by MedImmune LLC now part of AstraZeneca) as VP Development to build the development expertise needed to advance vaccines from research through product development. He was project leader of the intranasal influenza vaccine (FluMist™) during preclinical and clinical development and was instrumental in developing the improved refrigerator stable formulation of FluMist™. Dr. Patzer left Aviron and in 2003 co-founded Aridis. During his career he has had broad management responsibility in product development including analytical testing, preclinical animal testing, process and formulation development, QA/QC and project and portfolio management.

Dr. Patzer received a B.S. in mechanical engineering from Penn State University, a Ph.D. in Microbiology from the University of Virginia and was a Helen Hay Whitney Postdoctoral Fellow at Stanford University.